Cover Image
市場調查報告書

Ultragenyx Pharmaceutical Inc. 的產品平台分析

Ultragenyx Pharmaceutical Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256039
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
Ultragenyx Pharmaceutical Inc. 的產品平台分析 Ultragenyx Pharmaceutical Inc. - Product Pipeline Review - 2015
出版日期: 2015年11月18日 內容資訊: 英文 40 Pages
簡介

Ultragenyx Pharmaceutical Inc.是總公司位於美國的生物科技企業,正在開發針對重大運動神經障礙、肌肉無力、骨骼變形、骨痛、身高過矮、骨骼密度低等罕見的遺傳疾病之治療藥。

本報告提供Ultragenyx Pharmaceutical Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Ultragenyx Pharmaceutical Inc. 的基本資料

  • Ultragenyx Pharmaceutical Inc. 概要
  • 主要資訊
  • 企業資料

Ultragenyx Pharmaceutical Inc. :R&D概要

  • 主要的治療範圍

Ultragenyx Pharmaceutical Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品

Ultragenyx Pharmaceutical Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Ultragenyx Pharmaceutical Inc. :藥物簡介

  • aceneuramic acid
  • UX-007
  • UX-003
  • UX-002
  • UX-004

Ultragenyx Pharmaceutical Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Ultragenyx Pharmaceutical Inc. :最新的開發平台資訊

Ultragenyx Pharmaceutical Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07773CDB

Summary

Global Markets Direct's, 'Ultragenyx Pharmaceutical Inc. - Product Pipeline Review - 2015', provides an overview of the Ultragenyx Pharmaceutical Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ultragenyx Pharmaceutical Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Ultragenyx Pharmaceutical Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Ultragenyx Pharmaceutical Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Ultragenyx Pharmaceutical Inc.'s pipeline products

Reasons to buy

  • Evaluate Ultragenyx Pharmaceutical Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Ultragenyx Pharmaceutical Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Ultragenyx Pharmaceutical Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Ultragenyx Pharmaceutical Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ultragenyx Pharmaceutical Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Ultragenyx Pharmaceutical Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Ultragenyx Pharmaceutical Inc. Snapshot
    • Ultragenyx Pharmaceutical Inc. Overview
    • Key Information
    • Key Facts
  • Ultragenyx Pharmaceutical Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Ultragenyx Pharmaceutical Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Ultragenyx Pharmaceutical Inc. - Pipeline Products Glance
    • Ultragenyx Pharmaceutical Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Ultragenyx Pharmaceutical Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Ultragenyx Pharmaceutical Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Ultragenyx Pharmaceutical Inc. - Drug Profiles
    • aceneuramic acid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • UX-003
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • UX-007
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • UX-004
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ultragenyx Pharmaceutical Inc. - Pipeline Analysis
    • Ultragenyx Pharmaceutical Inc. - Pipeline Products by Target
    • Ultragenyx Pharmaceutical Inc. - Pipeline Products by Route of Administration
    • Ultragenyx Pharmaceutical Inc. - Pipeline Products by Molecule Type
    • Ultragenyx Pharmaceutical Inc. - Pipeline Products by Mechanism of Action
  • Ultragenyx Pharmaceutical Inc. - Recent Pipeline Updates
  • Ultragenyx Pharmaceutical Inc. - Dormant Projects
  • Ultragenyx Pharmaceutical Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Ultragenyx Pharmaceutical Inc., Key Information
  • Ultragenyx Pharmaceutical Inc., Key Facts
  • Ultragenyx Pharmaceutical Inc. - Pipeline by Indication, 2015
  • Ultragenyx Pharmaceutical Inc. - Pipeline by Stage of Development, 2015
  • Ultragenyx Pharmaceutical Inc. - Monotherapy Products in Pipeline, 2015
  • Ultragenyx Pharmaceutical Inc. - Partnered Products in Pipeline, 2015
  • Ultragenyx Pharmaceutical Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Ultragenyx Pharmaceutical Inc. - Pre-Registration, 2015
  • Ultragenyx Pharmaceutical Inc. - Phase III, 2015
  • Ultragenyx Pharmaceutical Inc. - Phase II, 2015
  • Ultragenyx Pharmaceutical Inc. - Preclinical, 2015
  • Ultragenyx Pharmaceutical Inc. - Pipeline by Target, 2015
  • Ultragenyx Pharmaceutical Inc. - Pipeline by Route of Administration, 2015
  • Ultragenyx Pharmaceutical Inc. - Pipeline by Molecule Type, 2015
  • Ultragenyx Pharmaceutical Inc. - Pipeline Products by Mechanism of Action, 2015
  • Ultragenyx Pharmaceutical Inc. - Recent Pipeline Updates, 2015
  • Ultragenyx Pharmaceutical Inc. - Dormant Developmental Projects,2015

List of Figures

  • Ultragenyx Pharmaceutical Inc. - Pipeline by Top 10 Indication, 2015
  • Ultragenyx Pharmaceutical Inc. - Pipeline by Stage of Development, 2015
  • Ultragenyx Pharmaceutical Inc. - Monotherapy Products in Pipeline, 2015
  • Ultragenyx Pharmaceutical Inc. - Partnered Products in Pipeline, 2015
  • Ultragenyx Pharmaceutical Inc. - Pipeline by Top 10 Target, 2015
  • Ultragenyx Pharmaceutical Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Ultragenyx Pharmaceutical Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Ultragenyx Pharmaceutical Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top